SG10201804513WA - Antibodies Against Fcrn And Use Thereof - Google Patents

Antibodies Against Fcrn And Use Thereof

Info

Publication number
SG10201804513WA
SG10201804513WA SG10201804513WA SG10201804513WA SG10201804513WA SG 10201804513W A SG10201804513W A SG 10201804513WA SG 10201804513W A SG10201804513W A SG 10201804513WA SG 10201804513W A SG10201804513W A SG 10201804513WA SG 10201804513W A SG10201804513W A SG 10201804513WA
Authority
SG
Singapore
Prior art keywords
fcrn
use
antibodies against
against fcrn
proteins
Prior art date
Application number
SG10201804513WA
Inventor
Christopher Tenhoor
Arumugam Muruganandam
Robert Charles Ladner
Clive Wood
Alan J Bitonti
James Stattel
Kevin Mcdonnell
Liming Liu
Jennifer DUMONT
Aaron Sato
Original Assignee
Dyax Corp
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US4815208P priority Critical
Priority to US4850008P priority
Application filed by Dyax Corp, Bioverativ Therapeutics Inc filed Critical Dyax Corp
Publication of SG10201804513WA publication Critical patent/SG10201804513WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058Antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/14Peptides, e.g. proteins
    • A61K49/16Antibodies; Immunoglobulins; Fragments thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1003Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups against receptors, cell-surface antigens, cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Abstract

ANTIBODIES AGAINST FCRN AND USE THEREOF This disclosure provides, inter alia, proteins that bind to FcRn, e.g. immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a 5 variety of disorders including autoimmune disorders. Figure 36
SG10201804513WA 2008-04-25 2009-04-24 Antibodies Against Fcrn And Use Thereof SG10201804513WA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US4815208P true 2008-04-25 2008-04-25
US4850008P true 2008-04-28 2008-04-28

Publications (1)

Publication Number Publication Date
SG10201804513WA true SG10201804513WA (en) 2018-07-30

Family

ID=41203902

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201804513WA SG10201804513WA (en) 2008-04-25 2009-04-24 Antibodies Against Fcrn And Use Thereof
SG2014004063A SG196839A1 (en) 2008-04-25 2009-04-24 Antibodies against fcrn and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2014004063A SG196839A1 (en) 2008-04-25 2009-04-24 Antibodies against fcrn and use thereof

Country Status (16)

Country Link
US (10) US8273351B2 (en)
EP (2) EP3348573A1 (en)
JP (3) JP6106854B2 (en)
KR (3) KR20170122286A (en)
CN (3) CN108467431A (en)
AU (1) AU2009238605B2 (en)
CA (1) CA2722082A1 (en)
ES (1) ES2650804T3 (en)
HK (2) HK1160868A1 (en)
IL (2) IL208846A (en)
MX (1) MX2010011679A (en)
NZ (1) NZ589451A (en)
SG (2) SG10201804513WA (en)
TW (3) TWI547287B (en)
WO (1) WO2009131702A2 (en)
ZA (1) ZA201007873B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201804513WA (en) 2008-04-25 2018-07-30 Dyax Corp Antibodies Against Fcrn And Use Thereof
WO2012167039A1 (en) * 2011-06-02 2012-12-06 Dyax Corp. Fc RECEPTOR BINDING PROTEINS
JP5855239B2 (en) 2012-04-23 2016-02-09 株式会社Nrlファーマ Lactoferrin fusion protein and a method of manufacturing the same
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
EP2970406B1 (en) * 2013-03-15 2017-12-13 Affibody AB New polypeptides
US20160075766A1 (en) * 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
JP2016531915A (en) * 2013-08-28 2016-10-13 ステムセントリックス, インコーポレイテッド Site specific antibodies conjugation methods and compositions
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
KR20160111937A (en) 2013-12-24 2016-09-27 아르젠-엑스 엔.브이. Fcrn antagonists and methods of use
EP3134733A4 (en) * 2014-04-25 2017-10-11 The Brigham and Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
AU2015253915B2 (en) * 2014-04-30 2018-05-10 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
EP3146040A1 (en) * 2014-05-19 2017-03-29 F.Hoffmann-La Roche Ag Method for producing antibodies using ovine b-cells and uses thereof
BR112017004189A2 (en) 2014-09-17 2017-12-12 Affibody Ab FcRn binding dimer, conjugate or fusion protein, and composition
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
CN106957365A (en) * 2016-01-11 2017-07-18 上海交通大学 Monoclonal antibody FnAb8 and application thereof
CN109790221A (en) * 2016-07-29 2019-05-21 动量制药公司 FCRN antibody and its application method
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
WO2018229249A1 (en) * 2017-06-15 2018-12-20 Ucb Biopharma Sprl Method for the treatment of immune thrombocytopenia

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
DE2901218A1 (en) 1979-01-13 1980-07-17 Byk Gulden Lomberg Chem Fab Ung of theophylline
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc Method for coupling liposomes.
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0317156B2 (en) 1987-11-09 1997-11-12 Becton Dickinson and Company Method for analysis of hematopoietic cells in a sample
AT439435T (en) 1991-03-01 2009-08-15 Dyax Corp Chimeric protein with micro-protein disulfide bonds with two or more and embodiments thereof
DE768377T1 (en) 1988-09-02 1998-01-02 Dyax Corp Production and selection of Rekombinantproteinen with different binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (en) 1990-07-10 2000-02-16 Medical Res Council Procedures for producing members of specific binding partners.
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5179107A (en) 1990-09-07 1993-01-12 Schering Corporation Antiviral quinolinone compounds
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
PT100379B (en) * 1991-04-10 1999-01-29 Scripps Research Inst heterodimeric receptors using phagemid libraries
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and derivatives chemical immuno including immotoxines
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for antibody screening
DE69326967D1 (en) 1992-01-17 1999-12-16 Lakowicz Joseph R Phasenmodulationsenergieübertragungsfluoroimmunassay
SE9201984D0 (en) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
DE69637481D1 (en) 1995-04-27 2008-05-15 Amgen Fremont Inc Dating from immunized Xenomäusen human antibodies to IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
DE69835143T2 (en) 1997-01-21 2007-06-06 The General Hospital Corp., Boston Selection of proteins using RNA-protein fusions
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AT340870T (en) 1998-04-03 2006-10-15 Compound Therapeutics Inc Addressable protein arrays
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ES2278463T3 (en) 1998-12-08 2007-08-01 Biovation Limited Method to reduce immunogenicity of proteins.
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6960178B2 (en) 2000-02-02 2005-11-01 Xepmed, Inc. Apparatus for enhanced plasmapheresis and methods thereof
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
DE60232672D1 (en) 2001-10-01 2009-07-30 Dyax Corp Multi-chain eukaryotic display-vectors and their uses
WO2003035842A2 (en) 2001-10-24 2003-05-01 Dyax Corporation Hybridization control of sequence variation
EP1660128A4 (en) 2003-08-08 2009-01-21 Univ New York State Res Found Anti-fcrn antibodies for treatment of auto/allo immune conditions
JP2009524664A (en) * 2006-01-25 2009-07-02 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク Anti--fcrn antibody for the treatment of self / allo-immune disease
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
EP1879920A2 (en) * 2005-04-29 2008-01-23 The Jackson Laboratory Fcrn antibodies and uses thereof
US20090092507A1 (en) * 2005-08-05 2009-04-09 Ramirez Jr Emilio A Fluid pump systems
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
PE07112009A1 (en) 2007-09-26 2009-07-15 Chugai Pharmaceutical Co Ltd constant region antibody mutant
AR068723A1 (en) 2007-10-05 2009-12-02 Glaxo Group Ltd Protein that binds to antigen that binds to human IL-23 and their uses
SG10201804513WA (en) 2008-04-25 2018-07-30 Dyax Corp Antibodies Against Fcrn And Use Thereof

Also Published As

Publication number Publication date
SG196839A1 (en) 2014-02-13
HK1207089A1 (en) 2016-01-22
CN102149729A (en) 2011-08-10
KR20110044729A (en) 2011-04-29
TWI547287B (en) 2016-09-01
CN108467431A (en) 2018-08-31
TWI453031B (en) 2014-09-21
JP2011523351A (en) 2011-08-11
US9260520B2 (en) 2016-02-16
IL241091A (en) 2018-02-28
TW201509430A (en) 2015-03-16
US20160222111A1 (en) 2016-08-04
AU2009238605A1 (en) 2009-10-29
NZ589451A (en) 2012-07-27
TW201630626A (en) 2016-09-01
US20130078262A1 (en) 2013-03-28
IL241091D0 (en) 2015-11-30
TWI593423B (en) 2017-08-01
US20140248287A1 (en) 2014-09-04
US8273351B2 (en) 2012-09-25
WO2009131702A3 (en) 2010-02-18
JP6499132B2 (en) 2019-04-10
US20160222112A1 (en) 2016-08-04
ZA201007873B (en) 2012-02-29
JP5989159B2 (en) 2016-09-07
CN102149729B (en) 2014-08-20
JP2017029149A (en) 2017-02-09
US20160222108A1 (en) 2016-08-04
US8815246B2 (en) 2014-08-26
US20160194397A1 (en) 2016-07-07
WO2009131702A9 (en) 2010-09-23
EP2310415B8 (en) 2017-12-13
JP6106854B2 (en) 2017-04-05
HK1160868A1 (en) 2015-07-31
CN104479017A (en) 2015-04-01
CA2722082A1 (en) 2009-10-29
US20130045218A1 (en) 2013-02-21
EP2310415A2 (en) 2011-04-20
IL208846D0 (en) 2011-01-31
AU2009238605B2 (en) 2014-11-06
ES2650804T3 (en) 2018-01-22
TW201010720A (en) 2010-03-16
MX2010011679A (en) 2011-05-23
US20160222110A1 (en) 2016-08-04
EP3348573A1 (en) 2018-07-18
KR20160079912A (en) 2016-07-06
EP2310415B1 (en) 2017-10-11
JP2015143230A (en) 2015-08-06
US20160222109A1 (en) 2016-08-04
KR101837329B1 (en) 2018-03-09
US20090324614A1 (en) 2009-12-31
WO2009131702A2 (en) 2009-10-29
KR101634719B1 (en) 2016-06-29
KR20170122286A (en) 2017-11-03
IL208846A (en) 2015-09-24

Similar Documents

Publication Publication Date Title
SI2603530T1 (en) Anti-fap antibodies and methods of use
TW201323438A (en) Binding agents
MX2008010561A (en) Functional antibodies.
GT201200189A (en) PCSK9 antagonists
RU2014136332A (en) The compositions and methods of using inhibitors csf1r
TW201514206A (en) Antibodies comprising chimeric constant domains
EA201390929A1 (en) Antibodies to pcsk9 and methods for their use
EA201391735A1 (en) Cd3-binding molecules capable of binding to human and cd3 cd3, non-human
MX336740B (en) Antibody fc variants.
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ580553A (en) Apoptotic anti- ige antibodies binding the membrane-bound ige
WO2006084264A3 (en) Cd20 antibody variants and uses thereof
MY159679A (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use
TW201111394A (en) Bispecific, tetravalent antigen binding proteins
WO2006073941A3 (en) Polypeptides that bind br3 and uses thereof
WO2006121422A3 (en) Antibodies against clostridium difficile toxins and uses thereof
NZ587107A (en) High affinity antibodies to human il-6 receptor
TW201023882A (en) Antibodies against human iL17 and uses thereof
TW200815469A (en) Compounds
SI2552955T1 (en) Antibodies with modified affinity to fcrn that promote antigen clearance
MX2011011925A (en) Tri- or tetraspecific antibodies.
EP2560684A4 (en) Fibronectin type iii domain-based multimeric scaffolds
MX2013001472A (en) Activatable bispecific antibodies
NZ602220A (en) Antibodies with ph dependent antigen binding
MX2010002683A (en) Homogeneous antibody populations.